Optical Mapping for Chromosomal Issues in Neurodevelopmental Disorders

The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopmental Disorders

Recruiting Observational Study
Anomalies Chromosome
Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
2 and older
Sex
Any
Study type
Observational
Participants needed
105 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Who this trial is looking for

This trial is looking for children aged 2 to 20 who have neurodevelopmental disorders and have a specific chromosomal abnormality that is hard to interpret. Participants will help improve understanding of these genetic issues through advanced mapping techniques.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am a child aged 2 to 20 years old.
  • I have been diagnosed with a neurodevelopmental disorder.
  • I have undergone chromosomal analysis that found a difficult-to-interpret chromosomal abnormality.

You may not be able to join if

  • I do not have medical insurance.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In neurodevelomental disorders, duplications are genomic variations that are difficult to interpret because their orientation cannot be defined by conventional techniques (ACPA and FISH). However, their orientation determines whether a gene disruption and potential loss of function can be validated or not. The same applies to complex chromosomal rearrangements that can involve duplications and del…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients: children aged 2 and over at the time of inclusion (and up to 20 years of age) * Patients followed at Robert Debré for TND who, as part of their care, * who have undergone chromosomal analysis by DNA microarray (ACPA) which has identified a chromosomal abnormality of …
Contacts

Anne-Claude TABET, MD, PhD

+331 40 03 57 10

anne-claude.tabet@aphp.fr

CONTACT

Jonathan LEVY, MD

+331 40 03 57 10

jonathan.levy@aphp.fr

CONTACT